RxDoctor Payments Data

Carrie Hager

Family · Salisbury, MDNPI 1922618677

Payments from drug & device makers

$1,167in general payments, 2019–2025

Across 27 payments — averaging $43.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$447
  • Lilly USA, LLC$194
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$100
  • Otsuka America Pharmaceutical, Inc.$99
  • Gilead$95
  • AbbVie$82
  • plus $150 from 7 others

What the payments were for

  • Food & beverage$1,167100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,167 in reported general payments places this provider in the 70th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$14,831
Medicare patients
139
Services billed
185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$33,452
JardianceEmpagliflozin31$30,721
TrulicityDulaglutide19$28,061
MounjaroTirzepatide18$25,771
Incruse ElliptaUmeclidinium Bromide31$14,275
Advair HfaFluticasone Propion/Salmeterol11$11,615
Breo ElliptaFluticasone/Vilanterol20$9,382
Arnuity ElliptaFluticasone Furoate14$2,851
Albuterol Sulfate HfaAlbuterol Sulfate100$2,763
Atorvastatin Calcium255$2,164
Rosuvastatin Calcium68$1,380
Ventolin HfaAlbuterol Sulfate13$1,134
Diclofenac Sodium27$938
Omeprazole97$908
Fluticasone Propionate91$856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$194$53,83237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,843 family providers in Maryland.

Other family in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →